Michael Brzica
PersonMentions
4
Relationships
0
Events
0
Documents
1
Relationship Network
Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons.
Drag nodes to reposition. Node size indicates connection count.
Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak).
Use legend and help buttons in the graph for more guidance.
No relationships found for this entity.
No events found for this entity.
HOUSE_OVERSIGHT_028419.jpg
This document, from a House Oversight file, details the business practices of the pharmaceutical company Celgene concerning its drugs Thalomid and Revlimid between 2000 and 2017. It outlines allegations of improper 'off-label' marketing, significant price increases, and aggressive strategies to extend its patent monopoly and block competition from generic drug makers. The document includes quotes from a Celgene executive, a federal regulatory agency, and a generic drug industry representative.
Congressional report/oversight document
2025-11-19
Total Received
$0.00
0 transactions
Total Paid
$0.00
0 transactions
Net Flow
$0.00
0 total transactions
No financial transactions found for this entity. Entity linking may need to be improved.
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity